Enovis Corp's stock touched a new 52‑week low of $19.12 on September 3, 2026, after sliding 18.65% over the prior week and posting a 1‑year decline of 39.14%.
For the second quarter of 2026 the company reported adjusted earnings of $0.90 per share, topping the consensus estimate of $0.85, while revenue came in at $582.78 million, in line with forecasts.
In the same period Enovis announced the acquisition of French surgical‑robotics firm eCential Robotics for an approximate €176 million total price, including an enterprise value of €155 million and potential milestone payments of up to €35 million.
Following the deal, analysts trimmed their price targets. Citizens lowered its target from $55 to $47 but kept a Market Outperform rating. BMO Capital cut its target from $30 to $27, citing expected margin pressure from the acquisition, while maintaining an Outperform stance.
Technical indicators show the stock in oversold territory, with the Relative Strength Index supporting that view. Analysts expect the company to return to profitability later in the year, though short‑term outlook remains cautious amid lingering cost pressures.
